FDA SCHEDULES PRE-NDA MEETING FOR SCENESSE®
12 October 2016 On 7 November the US Food and Drug Administration...
Read More
Media release: FDA, CLINUVEL TO DISCUSS SCENESSE® AT PRE-NDA MEETING
11 October 2016 CLINUVEL PHARMACEUTICALS LTD today announced that it will meet...
Read More
CLINUVEL Confirms Date of Annual General Meeting
09 October 2016 In accordance with ASX listing rules 3.13.1 and 14.3,...
Read More
Chair's Letter
19 September 2016 This summer our team supplied the first SCENESSE® (afamelanotide...
Read More
Appendix 4E - Preliminary Final Report 2015/16
24 August 2016 Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...
Read More
Lapse and Forfeit of Unlisted Conditional Performance Rights
23 August 2016 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...
Read More
CLINUVEL Newsletter - August 2016
16 August 2016 In the arduous journey from explorative concept to development...
Read More
Notice of Initial Substantial Holder
10 August 2016 Enclosed are the details of a notice of initial...
Read More
Appendix 3B
02 August 2016 New issue announcement, application for quotation of additional securities...
Read More
CLINUVEL completes pre-clinical study of SCENESSE® as combination therapy
02 August 2016 CLINUVEL prepares New Drug Application (NDA) for the treatment...
Read More
FDA accepts SCENESSE® clinical data package for NDA submission
17 July 2016 Clinuvel prepares New Drug Application (NDA) for the treatment...
Read More
FDA awards SCENESSE® Fast Track designation for treatment of EPP
05 July 2016 Executive summary: FDA awards Fast Track Designation¹ to expedite...
Read More
CLINUVEL’s SCENESSE® launched in Europe
20 June 2016 First commercial delivery, SCENESSE® approved as standard of care...
Read More